Balyasny Asset Management L.P. Makes New $274,000 Investment in TG Therapeutics, Inc. (NASDAQ:TGTX)

Balyasny Asset Management L.P. bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 9,100 shares of the biopharmaceutical company's stock, valued at approximately $274,000.

Several other large investors also recently made changes to their positions in TGTX. Quadrant Capital Group LLC lifted its position in shares of TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after acquiring an additional 975 shares during the period. Blue Trust Inc. boosted its position in shares of TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in TG Therapeutics by 460.7% during the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after acquiring an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC bought a new position in TG Therapeutics during the fourth quarter worth about $75,000. Institutional investors own 58.58% of the company's stock.

TG Therapeutics Stock Performance

NASDAQ:TGTX traded up $0.18 on Thursday, hitting $34.38. The company's stock had a trading volume of 722,081 shares, compared to its average volume of 2,984,571. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The stock has a fifty day moving average of $38.38 and a two-hundred day moving average of $34.09. The firm has a market capitalization of $5.46 billion, a P/E ratio of -344.13 and a beta of 2.21. TG Therapeutics, Inc. has a one year low of $15.16 and a one year high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.07) EPS. Research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TGTX. HC Wainwright restated a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a report on Tuesday, March 4th. Wall Street Zen upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.